Literature DB >> 34315423

Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events.

Shan-Shan Yang1, Lei Chen1, Ying Liu2, Hai-Jun Lu3, Bo-Jie Huang4, Ai-Hua Lin5, Ying Sun1, Jun Ma1, Fang-Yun Xie1, Yan-Ping Mao6.   

Abstract

BACKGROUND: The psychometric properties of the simplified Chinese version of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) have not been assessed. Therefore, we aimed to assess its validity, reliability, and responsiveness. PATIENTS AND METHODS: A Chinese version of the PRO-CTCAE and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (QLQ-C30) were distributed to 1580 patients from four cancer hospitals in China. Validity assessments included construct validity, measured by Pearson's correlations and confirmatory factor analysis (CFA), and known-groups validity, measured by t-tests. The assessment of reliability included internal consistency, measured by Cronbach's ɑ, and test-retest reliability, measured by the intraclass correlation (ICC). Responsiveness was assessed by standardized response means (SRMs).
RESULTS: Data from 1555 patients who completed the instruments were analyzed. The correlations were high between PRO-CTCAE items and parallel QLQ-C30 symptom scales (r > 0.60, p < 0.001), except for fatigue (severity: r = 0.49). Moreover, CFA showed the PRO-CTCAE structure was a good fit with the data (Root Mean Square Error of Approximation = 0.046). Known-groups validity was also confirmed. Cronbach's ɑ of all item clusters were greater than 0.9 and the median test-retest reliability coefficients of the 38 items were 0.85 (range = 0.71-0.91). In addition, the SRMs of PRO-CTCAE items were greater than 0.8, indicating strong responsiveness.
CONCLUSION: The simplified Chinese version of the PRO-CTCAE showed good reliability, validity, and responsiveness.
© 2021. The Author(s).

Entities:  

Keywords:  Chinese; PRO-CTCAE; Patient-reported outcomes; Reliability; Validity

Year:  2021        PMID: 34315423     DOI: 10.1186/s12885-021-08610-0

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  14 in total

Review 1.  Response burden and questionnaire length: is shorter better? A review and meta-analysis.

Authors:  Sindre Rolstad; John Adler; Anna Rydén
Journal:  Value Health       Date:  2011-08-02       Impact factor: 5.725

2.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

3.  Patient-reported outcomes in drug safety evaluation.

Authors:  E Basch
Journal:  Ann Oncol       Date:  2009-12       Impact factor: 32.976

4.  Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

Authors:  Massimo Di Maio; Ciro Gallo; Natasha B Leighl; Maria Carmela Piccirillo; Gennaro Daniele; Francesco Nuzzo; Cesare Gridelli; Vittorio Gebbia; Fortunato Ciardiello; Sabino De Placido; Anna Ceribelli; Adolfo G Favaretto; Andrea de Matteis; Ronald Feld; Charles Butts; Jane Bryce; Simona Signoriello; Alessandro Morabito; Gaetano Rocco; Francesco Perrone
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

5.  The missing voice of patients in drug-safety reporting.

Authors:  Ethan Basch
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

Review 6.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

7.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

8.  Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

Authors:  V Hagelstein; I Ortland; A Wilmer; S A Mitchell; U Jaehde
Journal:  Ann Oncol       Date:  2016-09-28       Impact factor: 32.976

9.  Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Tempei Miyaji; Yukiko Iioka; Yujiro Kuroda; Daigo Yamamoto; Satoru Iwase; Yasushi Goto; Masahiro Tsuboi; Hiroki Odagiri; Yu Tsubota; Takashi Kawaguchi; Naoko Sakata; Ethan Basch; Takuhiro Yamaguchi
Journal:  J Patient Rep Outcomes       Date:  2017-12-05

10.  Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).

Authors:  Cheng Kkf; S A Mitchell; N Chan; E Ang; W Tam; R Kanesvaran
Journal:  BMC Cancer       Date:  2020-11-26       Impact factor: 4.430

View more
  1 in total

1.  GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.

Authors:  Juanzi Zeng; Heming Wu; Donghua Liu; Liang Li; Jiaquan Li; Qiuming Wang; Min Ye; Qingyan Huang; Zhikang Yu; Jinfeng Zhang
Journal:  World J Surg Oncol       Date:  2022-06-22       Impact factor: 3.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.